According to our (Global Info Research) latest study, the global Rapid Influenza Diagnostic Test (RIDT) market size was valued at US$ 1283 million in 2025 and is forecast to a readjusted size of US$ 2019 million by 2032 with a CAGR of 6.8% during review period.
Rapid Influenza Diagnostic Tests (RIDTs) are in vitro diagnostic products based on immunochromatographic or immunofluorescence technology, designed to qualitatively detect the presence of Influenza A and B nucleoprotein antigens in respiratory specimens within 30 minutes. Product formats mainly include lateral-flow cassette tests, fluorescent immunoassay cartridges, and multiplex panels (e.g., Flu A/B + SARS-CoV-2). Upstream materials primarily consist of monoclonal and polyclonal antibodies, antigen controls, nitrocellulose membranes, plastic housings, and buffer reagents, supplied by specialized reagent and medical consumable manufacturers. Downstream clients include hospital laboratories, community clinics, pharmacies and OTC retailers, public health agencies, and home-testing users.
Based on due-diligence estimates, the global RIDT market in 2024 had an installed production capacity of approximately 320 million units, with sales of around 256 million units. The average selling price was about USD 4.5 per unit, and the average gross margin was approximately 67%. The market continues to grow steadily, driven by recurring flu seasons, enhanced epidemic surveillance, and rising demand for rapid self-testing. With the adoption of multiplex combo tests (e.g., Flu/COVID/RSV) and more sensitive fluorescent immunoassay platforms, the industry is expected to experience further consolidation and technological upgrading.
At present, the global Rapid Influenza Diagnostic Test (RIDT) market is experiencing steady expansion. Frequent mutations in influenza virus strains and the predictable recurrence of seasonal flu outbreaks have increased the demand for rapid testing among public health systems and medical institutions worldwide. RIDTs are gaining wider adoption across hospitals, community clinics, and home-testing scenarios. Since the COVID-19 pandemic, public awareness and acceptance of respiratory virus rapid testing have grown substantially, further driving RIDT utilization. In addition, regulatory authorities in several countries have relaxed approval processes for over-the-counter (OTC) diagnostic products, enabling faster penetration of home-use testing kits.
Looking ahead, the RIDT market is expected to evolve toward multiplex detection and higher sensitivity. With technological advancements, more manufacturers are integrating influenza testing with other respiratory pathogens such as COVID-19, RSV, and adenovirus, allowing “one-sample, multi-target” diagnostics. The integration of digital connectivity will enable real-time data transmission and improve epidemic surveillance efficiency. Meanwhile, emerging Asian markets—supported by large populations and improving primary healthcare infrastructure—are anticipated to become the main growth drivers for global RIDT demand.
Nevertheless, several challenges remain. RIDTs still show lower sensitivity and specificity compared with molecular diagnostic methods such as RT-PCR, leading to potential false negatives in some cases. Price fluctuations in raw materials, high supplier concentration, and varying regulatory standards across regions can increase operational risks and cost pressures for manufacturers. Additionally, rising product homogeneity intensifies market competition, making it difficult for smaller players to achieve economies of scale. Going forward, industry growth will increasingly depend on continuous technological innovation, product diversification, and robust compliance in quality management and regulatory frameworks.
This report is a detailed and comprehensive analysis for global Rapid Influenza Diagnostic Test (RIDT) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Rapid Influenza Diagnostic Test (RIDT) market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Rapid Influenza Diagnostic Test (RIDT) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Rapid Influenza Diagnostic Test (RIDT) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Rapid Influenza Diagnostic Test (RIDT) market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Rapid Influenza Diagnostic Test (RIDT)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Rapid Influenza Diagnostic Test (RIDT) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BD, Abbott, Quidel, Actim, Denka, Roche, Thermo Fisher Scientific, Meridian Bioscience, Sekisui Diagnostics, Princeton BioMeditech, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Rapid Influenza Diagnostic Test (RIDT) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Immunochromatography
Colloidal Gold Method
Others
Market segment by Sample Type
Nasal Swab
Throat Swab
Nasopharyngeal Swab
Others
Market segment by Antigen Target
Influenza A Antigen
Influenza B Antigen
Influenza A/B Antigen
Others
Market segment by Testing Scenario
Laboratory-Based Test Kits
Point-of-Care Test (POCT) Kits
Home-Use Self-Testing Kits
Others
Market segment by Application
Hospital
Clinics
Home
Others
Major players covered
BD
Abbott
Quidel
Actim
Denka
Roche
Thermo Fisher Scientific
Meridian Bioscience
Sekisui Diagnostics
Princeton BioMeditech
Access Bio
Response Biomedical
Guangzhou Wondfo Biotech
Jiangsu Bioperfectus Technologies
Hangzhou Biotest Biotech
Wantai BioPharm
Daan Gene
Kehua Bio-Engineering
Zhuhai Encode Medical Engineering
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Rapid Influenza Diagnostic Test (RIDT) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Rapid Influenza Diagnostic Test (RIDT), with price, sales quantity, revenue, and global market share of Rapid Influenza Diagnostic Test (RIDT) from 2021 to 2026.
Chapter 3, the Rapid Influenza Diagnostic Test (RIDT) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Rapid Influenza Diagnostic Test (RIDT) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Rapid Influenza Diagnostic Test (RIDT) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Rapid Influenza Diagnostic Test (RIDT).
Chapter 14 and 15, to describe Rapid Influenza Diagnostic Test (RIDT) sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Rapid Influenza Diagnostic Test (RIDT). Industry analysis & Market Report on Rapid Influenza Diagnostic Test (RIDT) is a syndicated market report, published as Global Rapid Influenza Diagnostic Test (RIDT) Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Rapid Influenza Diagnostic Test (RIDT) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.